Linkage analysis was performed on a large pedigree with an autosomal dominant platelet disorder and a striking propensity in affected family members to develop hematologic malignancy, predominantly acute myelogenous leukemia. We report the linkage of the autosomal dominant platelet disorder to markers on chromosome 21q22. Four genetic markers completely cosegregate with the trait and yield maximum ONVINCING EVIDENCE for the multistep pathogenesis of malignancy' for human tumors has come from the analysis of families with an inherited predisposition to develop cancer. In some families, one mutation is inherited in the germ line and subsequent somatic mutations are acquired during life, giving rise to the malignant phenotype. Examples include Wilms tumor,' Li-Fraumeini syndrome,3 retinobla~toma,~ and familial colon cancer.' Linkage analysis of certain pedigrees has led to the identification of several genes that, when mutant, dramatically increase the likelihood of developing cancer during an individual's lifetime. For colon cancer, these genes include the MSH2 gene linked to chromosome 2p in hereditary nonpolyposis colon cancer6 and the APC gene linked to chromosome 5q in families with inherited adenomatous polyposis coli. ' However, linkage studies have been less fruitful in the evaluation of hematologic malignancies, in part because of the rarity of familial syndromes. Most mutant genes associated with acute leukemias have been identified by virtue of their involvement in acquired chromosomal translocations. In most cases, the consequence of chromosome translocation in acute myelogenous leukemia (AML) has been expression of fusion transcripts containing one or more DNA-binding proteins. Examples include the PMLl and retinoic acid re- ceptor cu(RARa) fusion in t(l5; 17) associated with acute promyelocytic leukemia'; fusion of AMLl and E T 0 in t(8;21) AML, M2 subtype'; the core binding factor &smooth muscle myosin heavy chain (CBFP-SMMHC) fusion associated with inv( 16) myelomonocytic leukemia with eosinophilia"'; and fusion of HRX to several partners in leukemias with 1 lq23 translocations."~13 Translocation breakpoints are highly conserved in these fusion transcripts, suggesting a central role in the pathogenesis of AML.
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Although these mutations appear to be necessary for the eventual development of AML, several observations suggest that more than one mutation is required to give rise to the clinical phenotype of AML. First, clonal remission has been documented in AML in which patients in cytogenetic and morphologic remission have persistent clonal hematopoiesis by X-linked clonality analysis." Clonal hematopoiesis without clinical evidence of AML in these patients is consistent with persistent mutation after chemotherapy that imparts a growth advantage to a single clone but is not in itself sufficient for the development of the leukemic phenotype. Second, myelodysplastic syndromes (MDSs) are preleukemic syndromes in which multistep progression to AML can be documented by serial acquisition of cytogenetic abnormalities associated with progression of disease. Third, there are rare but informative families with an inherited tendency to develop AML analogous to other forms of inherited predisposition to malignancy as noted above. Unfortunately, inherited propensity to develop AML is quite rare. Reported pedigrees have been too small for generalized linkage studies, and it has often been difficult to reliably identify affected individuals before the development of AML.
The pedigree described by Dowton et all5 in 1985 circumvents many of these problems. The pedigree is large enough to consider a generalized linkage approach, and the propensity to develop AML is marked by an autosomal dominant platelet disorder that allows for unequivocal identification of affected individuals in the first decade of life. We report the linkage of this trait to markers on chromosome 21q22. Identification of the gene that is responsible for the platelet disorder may provide further insight into platelet production and function and may also identify early events in the molecular evolution of AML that are applicable to sporadic leukemias. to participate in the study. Informed consent and blood samples were obtained from the remaining 52 family members. Phenotypes were assigned to these individuals before the start of genotyping. and 29 family members were considered to be affected on the basis of both ( I ) clinical history of a bleeding tendency and (2) thrombocytopenia and/or abnormal platelet aggregation in response to epinephrine and arachidonic acid.
Because the hallmark of a bleeding dyscrasia is a history of clinically significant bleeding. family members were asked detailed questions to assess for abnormal hemostasis. including: spontaneous. frequent epistaxis: menorrhagia: ecchymoses or petechiae: and significant bleeding associated with surgical procedures or childbirth. All affected family members had a clinical history of a significant bleeding tendency.
In addition to clinical history, laboratory studies were used to confirm affection status. Of 29 affected family members. 28 had thrombocytopenia (platelet count, < 150,000/mL). whereas no clinically unaffected family member had thrombocytopenia. Serial complete blood counts since the time of the original report of this pedigree in 1985' show consistent and stable thrombocytopenia in 9 affected individuals. In I of 29 affected individuals with a clinical history of bleeding but with a normal platelet count (lh2.000/mL. patient IV-25). functional platelet abnormalities were confirmed by a prolonged Ivy bleeding time ( > l 5 minutes) and abnormal platelet aggregation studies. Abnormal platelet aggregation. consisting of loss of the second wave of aggregation in response to epinephrine and decreased aggregation in response to arachidonic acid (Fig 2) . was present in 20 of 20 affected individuals who were tested. Aggregation to ristocetin was normal (Fig 2) . Platelet aggregation studies were tested on 4 unaffected family members. none of whom showed abnormal platelet aggregation.
Three large branches of the family from the originally reported pedipx" were excluded from the linkage study because there was no evidence of segregation of the trait among individuals in these branches. DNA colkcfion c u d procmsirl,q. Blood for DNA extraction was collected from 55 family members as indicated in Fig I . Total genomic DNA was prepared according to standard methods with phenokhloroform extraction and ethanol precipitation."' Linkage analysis was performed using polymerase chain reaction (PCR) to amplify microsatellite repeat polymorphisms.",'K The majority of PCR primers were obtained from the Technology Access Section of the University of Utah Genome Mapping Center (Salt Lake City. UT); the remainder were purchased from Research Genetics Inc (Huntsville, AB). based on the Genethon linkage map of chromosome 21."' A single primer from each primer set was endlabeled by a kinase reaction consisting of 20 pmol primer, 2.0 mL IOX kinase buffer(New England Biolahs. Beverly. MA). 140 mCi of y-"P-deoxyadenosine triphosphate (3.000 Cihmol; New England Nuclear. Boston. MA). and 20 U of T4 polynucleotide kinase (New England Biolabs). The kinase reaction was incubated at 37°C for 30 minutes. and the enzyme was inactivated for 2 minutes at 90°C.
PCR amplification of the repeat polymorphisms was performed in 96-well trays using an MJ Research (Watertown, MA) thermal cycler. Reaction volumes were 25 mL and consisted of 20 ng of DNA; 2.5 mL of 10x PCR buffer resolved on a denaturing polyacrylamide gel (5% to 7% acrylamide, 32% formamide) and were visualized by autoradiography. Allelotypes were assigned to each family member by direct inspection of the autoradiograph. Linkage analysis. Two-point logarithm of difference (lod) scores were calculated using the MLINK subroutine of the LINKAGE software package, version 5.1.'' An autosomal dominant model of disease gene inheritance was assumed. A penetrance of 90% was used in the analysis. This penetrance was considered to be valid because there was no evidence of incomplete penetrance in the family; ie, no apparently unaffected individual has given rise to an affected offspring. Disease allele frequency was assumed to be 0.001. Lod H 0 ET AL scores were first calculated assuming equal allele frequenc~es for the markers and were then calculated a second time with allele frequencies estimated from the unrelated members of the pedigree. Estimates of c,,,,," were performed with the LODSCORE subroutine of LINKAGE. After significant lmkage was obtained with the initial marker UT7582/D21 S 141 3, seven markers in the 2 I q22 region were chosen from the published Cooperative Human Linkage Center (CHLC) map" for additional genotyping. Two other polymorphic short tandem repeat markers, D21S211 (CHLC ftp db version 2.0) and D21S216,'2 known to localize to this general region were also selected for genotypic analysis. To facilitate this mapping study. we attempted to place these two markers and the initial marker, UT7582, onto the CHLC framework map. This was accomplished with the CMAP and CILINK programs of LINKAGE.
RESULTS
Clinical description. A 44-year-old woman was referred to the Hematology/Oncology Clinic at the Brigham and Women's Hospital (Boston, MA) for evaluation of thrombocytopenia and refractory anemia. Clinical evaluation showed a white blood cell count of 18.7 X I03/mL, with 7% blasts, 42% PMN, 37% lymphocytes, 5% monocytes, 7% eosinophils, and 2% basophils. Bone marrow aspirate and biopsy specimen showed a moderately hypercellular marrow (30% to 40% fat), with 5% to 10% myeloid blasts, increased numbers of early dysplastic myeloid progenitors, severe erythroid hypoplasia, and dysplastic megakaryocytes. Karyotype analysis showed de1(5)(q31) and del(1 l)(q13) in 24 of 25 cells; 1 cell had a normal karyotype. Based on these findings, a diagnosis of MDS with possible evolution to AML was made. She subsequently developed AML and was treated with standard induction chemotherapy.
This patient was a member of a large kindred with a previously identified autosomal dominant disorder of platelet function and number (Fig 1) . Affected family members have a clinical history of a bleeding diathesis (29 individuals tested positive per 29 individuals tested); thrombocytopenia (platelet count, <50,000 to 150,000/mL in 27 of 29); prolonged bleeding times (in 20 of 20); an "aspirin-like'' platelet aggregation defect with an abnormal response to arachidonic acid and loss of the second wave of aggregation in response to epinephrine (in 20 of 20; Fig 2) ; and normal platelet size and morphology (data not shown). All affected family members with a clinically significant history of bleeding had laboratory abnormalities to support a bleeding diathesis. The platelet disorder in this family differs phenotypically from other described autosomal dominant platelet deficiencies whose findings typically include shortened platelet life span, unusually large platelets, increased number of bone marrow megakaryocytes, male predominance, morphologically abnormal platelets, neutrophil nuclear hypersegmentation, and eosinophilia."
As previously described," affected family members have a striking propensity to develop hematologic malignancy in the first through sixth decades of life, predominantly AML. Of 29 affected family members, 6 have developed AML, and 1 of 29 (Fig 1, patient IV-27 ) has developed lymphosarcoma. None of the 24 unaffected family members have developed any type of hematologic malignancy (Fig 1) . Moreover the 8 affected family members who have died, 6 have died from leukemia. Thus, inheritance of the gene that is responsible for the autosomal dominant platelet disorder is strongly correlated with subsequent development of myeloid malignancy. Because the incidence of AML in the general population is approximately 1 in 1O0,OOO per year,23 the genetic locus that causes the platelet defect may predispose to the development of myeloid malignancy or, at least, be tightly linked to the trait.
Linkage of familial platelet disorder (FPD) to chromosome 21. To find linked markers for this disease locus, a general linkage study was performed. Genotypes in the disease pedigree were collected from an evenly spaced set of highly polymorphic dinucleotide, trinucleotide, and tetranucleotide repeat marker No evidence for linkage was observed with the first 92 markers tested. Analysis of these markers excluded approximately half of the genome (data not shown).
Linkage to chromosome 21 was initially identified through marker UT7582D21S1413, which yielded a maximum lod score of 7.73 (6' = .032). Linkage analysis of adjacent markers confirmed localization of the FPD locus to this region of chromosome 21. Eight additional markers yielded maximum lod scores ranging from 1.44 to 10.48, and seven of these markers gave maximum lod scores greater than 3 (Table l). Moreover, four of nine markers tested, D21S263, D21S216, IFNAR, and D21S65, were completely linked to the disease locus and gave lod scores of 6.19, 4.89, 9.40, and 10.48, respectively (I9 = .001). The haplotype that consistently segregates with the disease locus for these same four markers is 6-3-3-10 (Fig 1) . The lod scores were calculated under the assumption of equal allele frequencies for all marker systems (Table 1) . When the analysis was repeated with the allele frequencies estimated from the disease pedigree, the resultant lod scores did not significantly change (data not shown).
To clarify the localization of the disease gene with respect to the markers used in this linkage study, a map of all of the markers was constructed starting with the CHLC framework map of chromosome 21.2' Six of these markers (Mfd338D21S1265, D21S263, IFNAR, D21S65, D21S167, and D2 IS 168) were already included in the published ge-5221 netic map. Two of the markers (UT7582D21S1413 and D21S211) were placed on the map only as confidence intervals with odds greater than 1,000: 1 (Fig 3) . The third marker (D21216) has not been typed in CEPH reference families; thus, its position could not be determined using Centre d'Etude du Polymorphisme Humaine (CEPH) data. However, the localization of this marker was estimated from twopoint linkage analysis performed within the disease pedigree. The results showed that D21S216 was completely linked to the marker IFNAR, with a lod score of 7.46 (0) Distally, the closest flanking marker is D21S167, because recombinations were observed in 2 affected individuals (Table 2). Proximally, the closest flanking and firmly mapped marker (confidence interval, 1,OOO:l) is Mfd338D21S126.5, with recombinations observed in 3 affected individuals. This region spans a genetic distance of 15.2 centimorgan (CM). The two markers placed on the framework map with confidence intervals, UT7582D21S1413 and D21.3211, also show recombination events between the disease locus in this family (Table 2) . From this information, we conclude that UT7582D21S1413 is likely to be a closer flanking marker than D21S1265, whereas the position of D21S211 relative to D21S167 cannot be inferred from recombinational events. Thus, Mfd338D21S1265 and D21S167 define the FPD critical region of approximately 15.2 CM within which the gene responsible for the trait is located (Fig 3) .
DISCUSSION
There is evidence that myeloid leukemias, like other malignancies, result from the acquisition of serial mutations.' Evidence in support of the multistep pathogenesis of AML includes (1) clonal remission from AMLI4; (2) preleukemic syndromes, such as MDS, that progress to AML with associated acquisition of karyotype abnormalities; and (3) rare families with an inherited predisposition to develop AML. We have characterized a large family with an autosomai dominant disorder of platelet function and number, and a striking propensity to develop AML. Using linkage analysis, we have determined that the gene responsible for the autosomal dominant platelet disorder is located on chromosome 21q22.1-22.2, within a 15.2-CM region delimited by markers Mfd33WD21S2165 and D21S167. This locus is either identical to, or tightly linked to, the propensity to develop AML.
The phenotype of this pedigree is similar to other smaller pedigrees reported in the literature, including a well-characterized pedigree with an inherited platelet storage pool defect associated with a high incidence of acute myeloid leukemia.*' Furthermore, in sporadic cases of AML and myeloproliferative syndromes, platelets may also have aspirin-like aggregation functional abnormalities. Thus, it is possible that the mutant gene responsible for the trait in this pedigree may also be involved in other familial leukemia syndromes and in the majority of leukemias in which there is no apparent inherited predisposition.
Genetic mapping of this disorder is an important first step in our efforts to identify the underlying gene. The placement of the FPD critical region on chromosome 21q22 is of particular interest, because ( I ) this locus has been previously implicated in AML through the (8;21) and (3;21) chromosomal translocations involving the AMLl gene; and (2) there is a potential association between the FPD gene and the hematologic abnormalities observed in Down syndrome. There are five candidate genes that map to the FPD locus, including AMLI, the interferon d,8 receptor (IFNAR), the cytokine receptor family 2-4 (CRF2-4), phosphoribosylglycinamide formyltransferase (GART), and SON.
IS a particularly attractive candidate gene because it has been previously implicated in leukemogenesis through its involvement in the t(8;21) translocation observed in the M2 subtype of AML,' as well as in the t(3;21) translocation associated with MDS, chronic myelogenous leukemia in blast crisis, and therapy-related AML.2y.3" AMLI has a 5' DNA-binding domain with significant homology to the Drosophila pair-rule segmentation gene, runt, and a 3' transactivating domain that potentiates the transcriptional activity of the DNA-binding domain.
Several different fusion partners have been identified for the AMLl gene in translocations associated with AML. These include the E T 0 gene in t(8; 2 1) and the EAP, MDS 1, and EVIl genes in t(3;21) translocations.'"." A common feature for each of these translocations is expression of the DNA-binding domain and disruption of the transactivating domain by the respective fusion partners. It has been speculated that the DNA-binding domain then has dominant negative activity in precluding normal transactivation of genes by the AMLI. Therefore, it is possible that an inherited missense or frameshift mutation that disrupts the AMLI transactivating domain could lead to abnormal hematopoiesis. However. the mechanism by which such a mutation would predispose to the eventual development of AML in affected individuals is unknown.
The IFNAR gene and the related CRF2-4 gene that lies in close proximity are also potential candidate Although the function and pattern of expression of the CRF2-4 gene is unknown, IFN mediates a variety of effects in hematopoietic cells through interaction with its receptor, including induction of expression of IFN-regulatory factor-l, which has been implicated in pathogenesis of MDSs. SON has significant homology with the transcription factors MYC and MOS." Each of these genes has been implicated in pathogenesis of hematologic malignancy and, therefore, may be involved in pathogenesis of disease in this pedigree. Sequence analysis of each of these candidate genes is underway.
The localization of the FPD trait to chromosome 21 is also of interest because the FPD locus may overlap with the genetic region responsible for Down syndrome (trisomy 21 1.
Children with Down syndrome may have hematologic abnormalities involving platelets and other hematopoietic cell lin-
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From LINKAGE OF FAMILIAL LEUKEMIA TO CHROMOSOME 21q22 5223 eages, which are often present at birth.35 These abnormalities include thrombocytosis, thrombocytopenia, polycythemia, anemia, leukocytosis, leukemoid reactions, and transient abnormal myelopoiesis. Although these abnormalities often resolve spontaneously, these patients are at a greatly increased risk of developing leukemia, including a preponderance of acute megakaryocytic leukemia over other subtypes such as acute lymphoblastic leukemia and AML.
Therefore, it is tempting to speculate that the gene responsible for FPD is also involved in the hematologic abnormalities observed in Down syndrome. In support of this hypothesis, recent physical mapping evidence indicates that the Down syndrome chromosome region36 lies in close proximity to the FPD critical region. Minimal regions involved in the expression of specific features of the complex Down syndrome phenotype have been identified by analyzing patients with partial trisomy of chromosome 21. A total of 13 of 24 major features of Down syndrome has been mapped to a single region on chromosome 21q22.2.36 This region is located between markers D21S17, proximally, and D21S55, distally. However, physical mapping information of the proximal portion of this region is limited. Recent efforts to refine the physical map have used the more accurately mapped marker D21S65 as the proximal anchor of the Down syndrome chromosome region.37 D21S65 is tightly linked to the AMLl gene and is contained in the central portion of the FPD critical region. Therefore, the gene responsible for the platelet disorder and for the propensity for developing myeloid malignancies in the family studied in this report may also play a role in hematologic abnormalities, including AML, that are observed in Down syndrome.
The mechanism by which the inherited trait causes abnormalities in platelet number and function is unclear at this time. It is possible that the platelet disorder is an epiphenomenon that merely acts as a marker for the underlying pathophysiology. In contrast to other hematopoietic cell lines, platelet abnormalities are easily identified both clinically and through laboratory studies. As such, it is difficult to ascertain if the disease trait in this family is restricted solely to megakaryocytes or if other myeloid lineages are affected as well. It is likely that this inherited mutation acts as a first step that predisposes to the development of malignancy in affected family members. The acquisition of subsequent somatic mutations during life is necessary for the development of malignancy.
Because this family inherits a predisposition to developing AML, it may offer a unique opportunity to study the very earliest events in the pathogenesis of hematologic malignancy. Identification and characterization of the gene responsible for causing this disorder may provide further insight into the molecular basis of platelet production and function as well as of leukemogenesis.
